Drug recall · August 5, 2026
Dabigatran Etexilate Capsules recall
Why: Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Dabigatran Etexilate Capsules, 150 mg, 60-count (6x10) blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268, NDC 0904-7255-68.
- Lots / codes
Lot: 25141583, Exp. April 30, 2027.
- Quantity
- 3,600 cartons x 6 x 10 (in blister pack)
- Company
- Ascend Laboratories, LLC, Bedminster, NJ
- Distribution
- USA Nationwide
- Initiated
- July 16, 2026 · Voluntary: Firm initiated
- Classified
- August 5, 2026
- Reported
- August 5, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Dabigatran etexilate
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.